Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 786 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HER2/Neu-Negative Breast Cancer Clear all
Terminated Phase 2 Interventional

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

NCT03858972
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel, Capecitabine
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Whittier, California • Lakewood, Colorado • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 6, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

NCT02040857
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib, Aromatase Inhibitor
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
10
States / cities
San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 6, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

NCT00546156
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Ian E. Krop, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Hooksett, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 6, 2026, 4:23 PM EDT
Recruiting Phase 2 Interventional

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

NCT06517212
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancers
Interventions
Tirzepatide
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 6, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

NCT01245205
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Akt inhibitor MK2206, lapatinib ditosylate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Sioux Falls, South Dakota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 6, 2026, 4:23 PM EDT
Recruiting Phase 1 Interventional

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

NCT06756932
View directory record Official record
Conditions
Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
BGB-21447, Fulvestrant, BGB-43395
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Iowa City, Iowa • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 4:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

NCT02139358
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Trastuzumab, Pertuzumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 6, 2026, 4:23 PM EDT
Active, not recruiting Phase 1 Interventional

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678
View directory record Official record
Conditions
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 6, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer

NCT01022138
View directory record Official record
Conditions
Breast Cancer
Interventions
HER2Bi-armed activated T cells, Cyclophosphamide, Laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 6, 2026, 4:23 PM EDT
Active, not recruiting Phase 1 Interventional Results available

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

NCT04288089
View directory record Official record
Conditions
Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
Interventions
Palbociclib (75, 100, 125 milligram [mg]), H3B-6545 (150, 300, 450 mg)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Sarasota, Florida • Boston, Massachusetts • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 6, 2026, 4:23 PM EDT
Active, not recruiting No phase listed Observational

Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging

NCT03568448
View directory record Official record
Conditions
HER2 Negative Breast Cancer
Interventions
Response monitoring (no intervention)
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 6, 2026, 4:23 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

NCT02154776
View directory record Official record
Conditions
Advanced or Metastatic Breast Cancer
Interventions
LEE011, Buparlisib, Letrozole
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Lafayette, Indiana • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 6, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Results available

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

NCT04081389
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Celecoxib, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Paclitaxel, Recombinant Interferon Alfa-2b, Rintatolimod
Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 6, 2026, 4:23 PM EDT
Suspended Not applicable Interventional

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

NCT02993068
View directory record Official record
Conditions
BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma
Interventions
Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
5,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 6, 2026, 4:23 PM EDT
Terminated No phase listed Observational

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

NCT05068726
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
18F Fluoroestradiol Radiopharmaceutical with PET/CT
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Flagstaff, Arizona • Cerritos, California • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 6, 2026, 4:23 PM EDT
Not listed Phase 2 Interventional

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

NCT05025735
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Dapagliflozin 10Mg Tab
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 6, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

NCT03321981
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Zenocutuzumab, Trastuzumab, Vinorelbine, Endocrine therapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Kansas City, Kansas • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 6, 2026, 4:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

NCT05455619
View directory record Official record
Conditions
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions
Evexomostat
Drug
Lead sponsor
SynDevRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Loma Linda, California • Newport, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 6, 2026, 4:23 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

NCT05095207
View directory record Official record
Conditions
Breast Cancer, Metastasis
Interventions
Abemaciclib, Bicalutamide
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 6, 2026, 4:23 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer

NCT01254136
View directory record Official record
Conditions
Breast Cancer
Interventions
INCB007839 300mg BID, Trastuzumab, Vinorelbine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Fayetteville, Arkansas • Duarte, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Oct 6, 2026, 4:23 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211
View directory record Official record
Conditions
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
30
States / cities
Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 6, 2026, 4:23 PM EDT
Terminated Early Phase 1 Interventional

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

NCT03361800
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions
Entinostat
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 6, 2026, 4:23 PM EDT
Recruiting Phase 1 Interventional

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

NCT07137871
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Avasopasem
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 6, 2026, 4:23 PM EDT
Completed No phase listed Observational

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer

NCT06686602
View directory record Official record
Conditions
Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer
Interventions
No drug
Other
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
13,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 6, 2026, 4:23 PM EDT